The annual peptide story can become misleading simply by covering only its largest commercial category. FDA’s June 17 warning letter to Wholesale Peptide is a narrower but useful record outside the familiar semaglutide and tirzepatide headlines.
Two products, not a market-wide ruling
The original FDA letter says the agency reviewed the website in May 2026. It names “Prostamax” and “Gonadorelin” and concludes that the offered products are unapproved new drugs. FDA’s reasoning concerns intended use in disease or effects on the body and the absence of approved applications for those products.
A footnote addresses the site’s “RESEARCH USE ONLY” and “not for human consumption” language. FDA says other product-labeling and website evidence establishes human drug intended use despite that disclaimer. Those are the agency’s findings about the reviewed offer. This is not a general ruling about every product with a similar name, every compounding pathway or every use of gonadorelin.
Why this belongs in the year review
For medspa owners and nurses, the record shows why a provider directory cannot stop at a GLP-1 category or treat “peptide” as one approval status. A company can span multiple product types, each with a different preparation, use and regulatory context. A claim-level reference is more informative than a single company-wide green or red badge.
The letter also illustrates why dates need their own fields. June 17 is the letter issue date; May is the website-review period; June 23 is the FDA page’s content date. Our October 29 retrieval does not mean FDA issued a new action in October. The timeline uses the issue date and preserves the other dates in this account.
What is still unresolved
FDA requested a written response within 15 business days of receipt. That request does not establish that a response was sent, accepted or sufficient. This review has not verified a company response, closeout letter, court outcome or current business status. It therefore neither declares the matter resolved nor assumes the conduct continues.
The practitioner implication is to ask a precise evidence question: what does the dated original record say about this seller and this offered product? It is not a recommendation to source a research product for human use, an efficacy claim or a substitute for qualified legal assessment.
Evidence record
Event date: 2026-06-17. Source review: 2026-10-29. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: expanded against the specifically cited source passages. Source review is not qualified clinical or legal review. Report a proposed correction through Contact us; do not include patient data.